Elicio Therapeutics started a new clinical trial of ELI-002 immunotherapy for KRAS Mutated Pancreatic Ductal Adenocarcinoma
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumor.
The trial is designed to enroll male and female 18 Years and older and is being conducted in the Henry Ford Cancer Institute, Detroit, Michigan, United States; Washington University School of Medicine, Saint Louis, Missouri, United States; Memorial Sloan Kettering Cancer Center, New York, New York, United States; Tennessee Oncology - Centennial Clinic, Nashville, Tennessee, United States; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
The study start date is March 19, 2021.
The patients that can be enrolled into this study include:
- KRAS/NRAS mutated (G12D or G12R) solid tumor - Positive for circulating tumor DNA despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable - Screening CT is negative for recurrent disease - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: - Presence of tumor mutations where specific therapy is approved - Known brain metastases - Use of immunosuppressive drugs.
The population that are excluded from participation:
- Presence of tumor mutations where specific therapy is approved - Known brain metastases - Use of immunosuppressive drugs.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT04853017.
